TACSTD2 and neoplasm: In this study, using CRISPR/Cas9-mediated ATF2-KO cells, they discovered that ATF2 acts as a tumor suppressor by inhibiting the cancer driver trophoblast cell surface antigen 2 (TROP2), which is associated with cell de-adhesion and cell migration without triggering EMT.